Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
D 17.81 -1.08% -0.20
ACAD closed down 1.91 percent on Thursday, July 18, 2024, on 1.56 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Jul 31
*** please verify all earnings dates ***
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up

Date Alert Name Type % Chg
Slingshot Bullish Bullish Swing Setup -1.08%
Upper Bollinger Band Walk Strength -1.08%
Overbought Stochastic Strength -1.08%
Upper Bollinger Band Walk Strength -2.97%
Overbought Stochastic Strength -2.97%
Upper Bollinger Band Touch Strength -2.97%
Pocket Pivot Bullish Swing Setup -4.38%
Upper Bollinger Band Walk Strength -4.38%
Weak + Overbought Other -4.38%
Above Upper BB Strength -4.38%

   Recent Intraday Alerts

Alert Time
10 DMA Support about 2 hours ago
Fell Below Previous Day's Low about 2 hours ago
Possible Inside Day about 3 hours ago
Down 1% about 4 hours ago
60 Minute Opening Range Breakdown about 4 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

ACADIA Pharmaceuticals Inc. Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Medication Alzheimer's Disease Chemical Compounds Parkinson's Disease Chronic Pain Schizophrenia Neurological Disorders Central Nervous System Disorders Nervous System Disorders Glaucoma Treatment Of Parkinson's Disease Urological Disorders Treatment Of Glaucoma Treatment Of Chronic Pain Treatment Of Alzheimer's Disease Treatment Of Schizophrenia Psychosis

Is ACAD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 32.59
52 Week Low 14.55
Average Volume 1,787,058
200-Day Moving Average 21.28
50-Day Moving Average 15.80
20-Day Moving Average 16.61
10-Day Moving Average 17.51
Average True Range 0.62
RSI (14) 66.10
ADX 34.74
+DI 36.07
-DI 14.96
Chandelier Exit (Long, 3 ATRs) 17.07
Chandelier Exit (Short, 3 ATRs) 16.47
Upper Bollinger Bands 18.82
Lower Bollinger Band 14.40
Percent B (%b) 0.81
BandWidth 26.59
MACD Line 0.71
MACD Signal Line 0.50
MACD Histogram 0.2169
Fundamentals Value
Market Cap 2.96 Billion
Num Shares 164 Million
EPS -0.91
Price-to-Earnings (P/E) Ratio -19.78
Price-to-Sales 6.85
Price-to-Book 11.94
PEG Ratio -0.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.17
Resistance 3 (R3) 19.20 18.85 18.98
Resistance 2 (R2) 18.85 18.55 18.83 18.91
Resistance 1 (R1) 18.42 18.36 18.25 18.39 18.84
Pivot Point 18.07 18.07 17.98 18.05 18.07
Support 1 (S1) 17.64 17.77 17.47 17.61 17.16
Support 2 (S2) 17.29 17.58 17.27 17.09
Support 3 (S3) 16.86 17.29 17.03
Support 4 (S4) 16.83